Sign in Subscribe
Trademarks

Trademark Application Filed for "MAZVURXA" by Celgene Corporation

Strategic Insights

— 1 min read

Celgene Corporation's parent company, Bristol-Myers Squibb Company, has filed a trademark application for the name "MAZVURXA". This application was made available to the public on September 30, 2025. The application covers a wide range of pharmaceutical preparations for human use, including treatments for obesity, cardiovascular diseases, central nervous system diseases, and various types of cancer, among others.

Key Takeaways:

  • The trademark application for "MAZVURXA" covers pharmaceutical preparations for human use, including treatments for various diseases and disorders.
  • The application includes treatments for obesity, cardiovascular diseases, central nervous system diseases, and various types of cancer.
  • The application also includes pharmaceutical preparations for the treatment of COVID-19 and respiratory diseases.
  • The trademark application was made available to the public on September 30, 2025.
  • The applicant is Xiomara Triana Bristol-Myers Squibb Company, on behalf of Celgene Corporation.
  • The application was made for various classes of goods and services, including pharmaceutical preparations, immunotherapy preparations, and diagnostic radiopharmaceutical preparations.
  • The application includes treatments for cystic fibrosis and cognitive disorders, such as Alzheimer's disease.
  • The application was submitted to the registrar on September 30, 2025.

Statistics:

  • The serial number for this application is 98584264.
  • The international trademark goods and services class code for this trademark application is 005.
  • The application was made available to the public on September 30, 2025.
  • The application covers a wide range of pharmaceutical preparations for human use, including treatments for various diseases and disorders.
  • The application includes treatments for obesity, cardiovascular diseases, central nervous system diseases, and various types of cancer.

Sources:

  • NewsRx (NewsRx.Asia)
  • United States Patent and Trademark Office (USPTO)

Read more